2024
Co-Morbidity Differences Associated With Long-Term Amputation and Repeat Revascularization Rates After Femoropopliteal Artery Intervention for Intermittent Claudication by Sex, Race, and Ethnicity
Altin S, Parise H, Hess C, Rosenthal N, Julien H, Curtis J. Co-Morbidity Differences Associated With Long-Term Amputation and Repeat Revascularization Rates After Femoropopliteal Artery Intervention for Intermittent Claudication by Sex, Race, and Ethnicity. The American Journal Of Cardiology 2024, 226: 40-49. PMID: 38834142, DOI: 10.1016/j.amjcard.2024.05.021.Peer-Reviewed Original ResearchNon-Hispanic patientsHispanic patientsIntermittent claudicationPeripheral vascular interventionsBlack patientsWhite patientsAmputation rateIndex limb amputationHazard ratioCox proportional hazards regression modelsDisease-specific issuesProportional hazards regression modelsHazards regression modelsBaseline characteristicsLimb amputationMajor amputationUnadjusted ratesAssociated with higher ratesHealthcare databasesBlack raceSecondary outcomesPrimary outcomeAmputationRevascularization ratesComparison group
2023
Long-Term Patient Outcomes After Femoropopliteal Peripheral Vascular Intervention in Patients With Intermittent Claudication
Altin S, Parise H, Hess C, Rosenthal N, Creager M, Aronow H, Curtis J. Long-Term Patient Outcomes After Femoropopliteal Peripheral Vascular Intervention in Patients With Intermittent Claudication. JACC Cardiovascular Interventions 2023, 16: 1668-1678. PMID: 37438035, DOI: 10.1016/j.jcin.2023.05.001.Peer-Reviewed Original ResearchConceptsPeripheral vascular interventionsIndex limb amputationAmputation rateIntermittent claudicationMajor amputationRevascularization ratesVascular interventionsCox proportional hazards regressionLong-term patient outcomesMajor amputation rateProportional hazards regressionKaplan-Meier estimatesFurther risk factorsLimb amputation rateClinical trial dataIndex limbIC patientsSecondary outcomesPrimary outcomeHazards regressionRisk factorsPatient outcomesLimb amputationHealthcare databasesPatientsChocolate Touch Versus Lutonix Drug-Coated Balloon for Femoropopliteal Lesions in Diabetes: The Chocolate Touch Study.
Böhme T, Zeller T, Shishehbor M, Werner M, Brodmann M, Parise H, Holden A, Lichtenberg M, Parikh S, Kashyap V, Pietras C, Tirziu D, Beschorner U, Krishnan P, Niazi K, Wali A, Lansky A. Chocolate Touch Versus Lutonix Drug-Coated Balloon for Femoropopliteal Lesions in Diabetes: The Chocolate Touch Study. Journal Of Endovascular Therapy 2023, 15266028231179589. PMID: 37314243, DOI: 10.1177/15266028231179589.Peer-Reviewed Original ResearchLutonix drug-coated balloonDrug-coated balloonsPrimary safety endpointDM statusFemoropopliteal diseaseDiabetes mellitusSafety endpointFemoropopliteal lesionsSimilar safetyHigh-risk patient populationFemoropopliteal artery lesionsIschemic rest painNon-DM patientsSymptomatic femoropopliteal lesionsPrimary efficacy endpointMajor adverse eventsTherapy of choiceDrug-Coated BalloonMajor amputationRest painEfficacy endpointPrimary patencyAdverse eventsArtery lesionsDiabetes status
2022
Randomized Trial of Chocolate Touch Compared With Lutonix Drug-Coated Balloon in Femoropopliteal Lesions (Chocolate Touch Study)
Shishehbor MH, Zeller T, Werner M, Brodmann M, Parise H, Holden A, Lichtenberg M, Parikh SA, Kashyap VS, Pietras C, Tirziu D, Ardakani S, Beschorner U, Krishnan P, Niazi KA, Wali AU, Lansky AJ. Randomized Trial of Chocolate Touch Compared With Lutonix Drug-Coated Balloon in Femoropopliteal Lesions (Chocolate Touch Study). Circulation 2022, 145: 1645-1654. PMID: 35377157, DOI: 10.1161/circulationaha.122.059646.Peer-Reviewed Original ResearchConceptsLutonix drug-coated balloonDrug-coated balloonsEnd pointPrimary efficacy end pointPrimary safety end pointIndependent clinical events committeeIschemic rest painPrimary efficacy rateEfficacy end pointPrimary end pointSafety end pointClinical events committeeMajor adverse eventsRate of restenosisDrug-Coated BalloonNoninferiority end pointSafety event rateAverage lesion lengthMajor amputationPopliteal diseaseRest painBailout stentingEfficacy ratePrimary patencyAdverse events